MA-ANTERRA-CAPITAL
18.5.2022 07:02:06 CEST | Business Wire | Press release
A crushing pandemic and, more recently, the Ukraine war have convinced investors more than ever that the world needs to radically change how it produces, distributes and consumes food, says Adam Anders, managing partner of the international food and agriculture specialist venture capital firm Anterra Capital (“Anterra”).
Anders: “The pandemic highlighted the fragility and adverse health impacts of our current food system: soaring prices, empty shelves in stores; the fact that unhealthy diets are a major risk factor for getting Covid; that the way we treat farm animals could trigger the next pandemic. Post our final closing, the devastating impact of the Ukraine War on the global food supply has increased the awareness among investors even further. This, plus our focus on deploying proven biotech and digital solutions to shake up the lagging Food and Ag-sector, go a long way in explaining the higher than expected interest in our second fund.”
Anterra is proud to announce the closing of its second fund, with commitments in excess of $260 million. All investors from Anterra’s first fund returned in Fund II, led by Rabo Investments and Eight Roads Ventures. This fund also welcomes an international influx of new investors, ranging from pension funds and sovereign wealth funds to family offices and tech entrepreneurs from other sectors.
Anders: ”A new crop of mainstream investors is ready to get involved. Many already believed that the advances of the Green Revolution came at a hefty price. It gave us cheap fertilizer and powerful pesticides for growing plants; and growth hormones and antibiotics in animal production. But its obsession with yield is also destroying ecosystems and our own health. The pandemic gave the final push. Investors realize they can help build a resilient and regenerative food system and make excellent returns at the same time.”
One other unexpected outcome of the pandemic is that it has changed the outlook for using biotech in food and ag. Traditionally, this has been met with substantial public resistance. But since the roll-out of mRNA vaccines, billions of people have witnessed the positive power of biotech firsthand.
Anders: “Growing public acceptance of biotech solutions and gene-editing thanks to mRNA-vaccines, is an important shift. Biotech advances will also play a critical role in making food and agriculture more resilient and less carbon intensive; from fighting and preventing infectious diseases that jump from animals to humans; to developing more sustainable crop health solutions.”
Anterra believes that biotech and digital solutions are the two key technologies that will transform the food and agricultural sector. Through this technological lens Anterra seeks out entrepreneurs across the value-chain, ranging from ag fintech, crop science and animal health to human nutrition and consumer tech. Where it feels opportunities are being missed, Anterra also incubates companies itself: since 2018, Anterra has built five successful start-ups from scratch. At the same time, technology does not have to be cutting-edge to make its mark in the sector.
Anders: “Technology-wise food and ag lags 20 years behind sectors like human health and banking, so you don’t necessarily need the latest, cutting edge technology to transform it. Our incubated companies focus on deploying biotech and digital solutions that are established elsewhere, but are new to food and ag. I can confidently say we are unique in that approach. It’s an advantage of operating in a slow-moving sector: you can innovate in a slightly de-risked way.”
Executing this strategy, Anterra has built a diverse portfolio of innovators, ranging from entrepreneurs developing the next generation of targeted pesticides with low environmental impact, like Enko and Vestaron; start-ups improving animal and human health, like Invetx, Animol and Caribou Biosciences (co-founded by Nobel-prize winner Jennifer Doudna); companies empowering farmers with field data, access to finance, transparent pricing and direct distribution channels, like ProducePay and Agriconomie; and consumer tech-driven businesses transforming how we choose, buy and think about food, like LaFourche and Lollipop.
Anders: “Our strategy and years of experience are paying off. We look forward to supporting the next generation of great entrepreneurs and building a better food system.”
About Anterra
With offices in Amsterdam and Boston, Anterra Capital is an international specialist venture capital investor dedicated to financing the growth of technology-driven companies with incredible potential in food, agriculture, and animal health. Supported by multinational institutional investors, family offices and like-minded entrepreneurs, Anterra provides patient strategic capital to innovative companies sustainably transforming our global food system. Further information: www.anterracapital.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220517006310/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
Beerenberg Prevails in Patent Case Against Aspen Aerogels29.6.2026 07:00:00 CEST | Press release
The ruling confirms that Beerenberg did not infringe Aspen Aerogels’ patents. The Korean Patent Court has invalidated three of Aspen Aerogels’ patents related to improved hydrophobic aerogel material. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260628192007/en/ Beerenberg delivers high-end insulation solutions built for performance, reliability, and long-term value. (Photo: Beerenberg) The ruling confirms the conclusion of the Intellectual Property Trial and Appeal Board (IPTAB) that the patents did not meet the necessary requirements for patentability. Beerenberg, which specializes in high-end insulation products, welcomes the court’s decision. “We are pleased that the case has now been concluded and that any uncertainty regarding the infringement claims has been removed,” says CEO Arild Apelthun. About Beerenberg Beerenberg has delivered cost-efficient solutions to a wide range of industrial enterprises for 49 years. Th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
